FDA Commissioner Says First Psychedelic Drug Could Be Approved This Summer

FDA Commissioner Marty Makary told NBC News that the first psychedelic drug could be approved in the U.S. as soon as this summer, after the FDA issued national priority vouchers to three companies studying psilocybin and methylone for mental health conditions.

Objective Facts

FDA Commissioner Marty Makary told NBC News that the first psychedelic drug could be approved in the U.S. as soon as this summer following an executive order that President Donald Trump signed directing FDA Commissioner Dr. Marty Makary to prioritize psychedelic drugs that have been granted "breakthrough therapy" status. On Friday, the FDA issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD, with Compass Pathways, the Usona Institute and Transcend Therapeutics receiving the vouchers. The vouchers shorten the FDA's review process from its standard 10 to 12 months to just one to two months. Democratic members of Congress have noted that vouchers have gone to companies that are politically favored by the White House, raising questions about the propriety of the fast-track program.

Left-Leaning Perspective

The American Psychiatric Association said it "welcomes federal investment in research into psychedelic therapies" as potential treatment options for serious mental illnesses, but the organization has concerns about fast-tracking FDA approvals unless there is sufficient rigorous clinical trial data, with CEO Dr. Marketa Wills stating in an email that "current scientific evidence is not sufficient to support use of these therapies outside of approved research settings" and that "rigorous study, strong patient protections, and physician-led oversight will be essential to ensure safety and effectiveness". The APA advocates for a rigorous, research-driven approach with the organization's leadership emphasizing that "solid evidence and patient safety need to be the priority" and that "psychiatrists should play a central role in evaluating and delivering new treatments". Democratic members of Congress have noted that vouchers have gone to companies that are politically favored by the White House, including those that have agreed to cut prices on their medications. Critics of the priority voucher program say it was put in place without seeking input from Congress, and could ultimately undermine trust in the FDA's regulatory process by opening the door for companies to make financial contributions to the administration in an attempt to secure such a voucher. Some analysts argue the political embrace of psychedelics becomes "deeply contradictory," noting that Trump, Perry, and other figures now promoting psychedelic therapies have supported sweeping tax and spending legislation that "strips away the very forms of recovery capital the research shows are essential". Left-leaning coverage has emphasized safety concerns over enthusiasm. Trump's action surprised many longtime advocates and researchers in the psychedelic field, given that ibogaine is known to sometimes trigger potentially fatal heart problems, with the National Institutes of Health having discontinued work on the drug in the 1990s due to its "cardiovascular toxicity". In 2024, the FDA rejected MDMA for treating PTSD despite intense political pressure, with the agency telling the drug company that there wasn't enough evidence the therapy was safe and effective, and an independent advisory committee highlighted serious concerns including poor study design, sexual misconduct allegations during trials, and potential health risks including heart problems and abuse.

Right-Leaning Perspective

President Trump framed the directive as ensuring that people suffering from debilitating symptoms "might finally have a chance to reclaim their lives and lead a happier life," saying his directive will help "dramatically accelerate" access to potential treatments. Conservative podcaster Joe Rogan and former Navy SEAL Marcus Luttrell appeared at the Oval Office event, with Luttrell telling Trump "You're going to save a lot of lives through it. It absolutely changed my life for the better". Trump's move is drawing support from those praising its potential to transform mental health treatment, particularly for veterans, with former Marine Corps Lieutenant Colonel Jay Kopelman, CEO of Mission to Live Foundation, stating that the action "opens a pathway to research that will further open doors to expedited approval of this life-saving medicine as a treatment for our veterans". Kabir Nath, CEO of Compass Pathways, told TIME he was "very pleased to see that the grounding for the executive order was the need to get new treatment options to patients who are urgently in need of them". Mason Marks noted the executive order "really represents shifting attitudes towards psychedelics, and that could have a much larger impact in the future". Trump's announcement follows pledges by Health Secretary Robert F. Kennedy Jr. and other administration officials to ease access to psychedelics for medical use, an issue that has won rare bipartisan support. Right-leaning support emphasizes the mental health crisis and veteran suffering. Veteran organizations and psychedelic advocates have long contended that ibogaine has great promise for hard-to-treat conditions such as post-traumatic stress disorder and opioid addiction, with Trump's announcement following pledges by Health Secretary Robert F. Kennedy Jr. to ease access to psychedelics for medical use. Supporters acknowledge that ibogaine's primary risk is its "cardiotoxicity properties" that "can prolong the QT interval in the heartbeat, which can lead to arrhythmia or even heart attack," but note this risk is mitigated by "rigorous medical examinations" and monitoring during treatment.

Deep Dive

The specific angle of this story is FDA Commissioner Marty Makary's statement about summer approval timing and the actual voucher announcement on April 24. The context: President Trump signed an executive order on April 18 directing the FDA to prioritize psychedelic drug reviews with breakthrough therapy designations. This represents a significant policy shift from decades of strict prohibition, driven partly by veteran advocacy and partly by prominent Trump allies like Joe Rogan and Rick Perry who have championed ibogaine. What each side gets right: Proponents are correct that serious mental health crises exist and that preliminary research suggests psychedelics may help treatment-resistant conditions. The FDA's own Breakthrough Therapy designations acknowledge early promise. Critics are correct that the 2024 MDMA rejection showed serious safety concerns can emerge during trials—sexual misconduct allegations, cardiac risks, incomplete efficacy data—and that rushing approvals without comparable data for psilocybin or methylone carries real risk. The American Psychiatric Association's cautious position reflects legitimate concern that fast-tracking without sufficient data could harm the field's credibility. What gets left out: Right-leaning coverage largely omits that the Stanford ibogaine study lacked a placebo control (essential for rigorous research) and enrolled only 30 veterans in Mexico, not the U.S. It also downplays the 30+ deaths associated with ibogaine in medical literature. Left-leaning coverage sometimes underplays the genuine mental health crisis context and veteran suffering that motivates this push. Both sides underemphasize that even if approved, these would require specialized clinical settings and trained therapists—not pharmacy pickups—limiting real-world access for most suffering Americans. What to watch: The critical question is whether any of the three priority voucher recipients can demonstrate safety and efficacy within their accelerated timelines. FDA Commissioner Makary's summer timeline is aggressive; most drug approvals take years even on fast-tracks. The ibogaine cardiac risk issue may prove decisive—if Phase 1 trials show unacceptable safety signals, approval could be impossible regardless of political pressure. Additionally, watch whether Democratic Congressional pressure succeeds in scrutinizing the voucher allocation process itself, particularly given Peter Thiel's investment in psychedelic companies and questions about whether companies cut prices to secure favors. Finally, monitor whether the Right to Try Act provision for ibogaine becomes a backdoor to expanded access before proper trials complete.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

FDA Commissioner Says First Psychedelic Drug Could Be Approved This Summer

FDA Commissioner Marty Makary told NBC News that the first psychedelic drug could be approved in the U.S. as soon as this summer, after the FDA issued national priority vouchers to three companies studying psilocybin and methylone for mental health conditions.

Apr 24, 2026· Updated Apr 25, 2026
What's Going On

FDA Commissioner Marty Makary told NBC News that the first psychedelic drug could be approved in the U.S. as soon as this summer following an executive order that President Donald Trump signed directing FDA Commissioner Dr. Marty Makary to prioritize psychedelic drugs that have been granted "breakthrough therapy" status. On Friday, the FDA issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD, with Compass Pathways, the Usona Institute and Transcend Therapeutics receiving the vouchers. The vouchers shorten the FDA's review process from its standard 10 to 12 months to just one to two months. Democratic members of Congress have noted that vouchers have gone to companies that are politically favored by the White House, raising questions about the propriety of the fast-track program.

Left says: The American Psychiatric Association welcomes research but has concerns about fast-tracking approvals without sufficient clinical trial data, with the organization's CEO emphasizing that current scientific evidence is insufficient to support use outside approved settings. Democratic members of Congress note vouchers have gone to companies politically favored by the White House.
Right says: Trump framed the directive as ensuring people with debilitating symptoms "might finally have a chance to reclaim their lives," saying his directive will help "dramatically accelerate" access. Conservative supporters like podcaster Joe Rogan and former Navy SEAL Marcus Luttrell participated in the announcement, with Luttrell praising the move.
✓ Common Ground
The American Psychiatric Association and Trump administration agree that federal investment in research into psychedelic therapies is warranted as potential treatment options for serious mental illnesses.
Multiple sources acknowledge that psychedelic medical research and access "has won rare bipartisan support".
Several voices across the political spectrum acknowledge that recent studies have shown veterans treated with ibogaine had improvements in symptoms of traumatic brain injury, including PTSD, depression and anxiety.
Both supporters and skeptics acknowledge the importance of clinical trials, with the American Psychiatric Association's leadership and FDA Commissioner Makary both emphasizing that development must be "grounded in sound science and rigorous clinical evidence" and that "psychiatrists should play a central role in evaluating and delivering new treatments".
Objective Deep Dive

The specific angle of this story is FDA Commissioner Marty Makary's statement about summer approval timing and the actual voucher announcement on April 24. The context: President Trump signed an executive order on April 18 directing the FDA to prioritize psychedelic drug reviews with breakthrough therapy designations. This represents a significant policy shift from decades of strict prohibition, driven partly by veteran advocacy and partly by prominent Trump allies like Joe Rogan and Rick Perry who have championed ibogaine.

What each side gets right: Proponents are correct that serious mental health crises exist and that preliminary research suggests psychedelics may help treatment-resistant conditions. The FDA's own Breakthrough Therapy designations acknowledge early promise. Critics are correct that the 2024 MDMA rejection showed serious safety concerns can emerge during trials—sexual misconduct allegations, cardiac risks, incomplete efficacy data—and that rushing approvals without comparable data for psilocybin or methylone carries real risk. The American Psychiatric Association's cautious position reflects legitimate concern that fast-tracking without sufficient data could harm the field's credibility.

What gets left out: Right-leaning coverage largely omits that the Stanford ibogaine study lacked a placebo control (essential for rigorous research) and enrolled only 30 veterans in Mexico, not the U.S. It also downplays the 30+ deaths associated with ibogaine in medical literature. Left-leaning coverage sometimes underplays the genuine mental health crisis context and veteran suffering that motivates this push. Both sides underemphasize that even if approved, these would require specialized clinical settings and trained therapists—not pharmacy pickups—limiting real-world access for most suffering Americans.

What to watch: The critical question is whether any of the three priority voucher recipients can demonstrate safety and efficacy within their accelerated timelines. FDA Commissioner Makary's summer timeline is aggressive; most drug approvals take years even on fast-tracks. The ibogaine cardiac risk issue may prove decisive—if Phase 1 trials show unacceptable safety signals, approval could be impossible regardless of political pressure. Additionally, watch whether Democratic Congressional pressure succeeds in scrutinizing the voucher allocation process itself, particularly given Peter Thiel's investment in psychedelic companies and questions about whether companies cut prices to secure favors. Finally, monitor whether the Right to Try Act provision for ibogaine becomes a backdoor to expanded access before proper trials complete.

◈ Tone Comparison

Left-leaning outlets emphasize caution and skepticism, describing drugs as "controversial" and highlighting "serious safety risks," with focus on regulatory concerns and insufficient evidence. Right-leaning sources use positive framing like "life-saving medicine" and "dramatically accelerate," emphasizing veteran testimonials and the mental health crisis. Both sides acknowledge the need for scientific rigor, but diverge sharply on whether current evidence supports fast-tracking.